Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.

Item
http://www.wikidata.org/entity/Q33408584
Epigenetic treatment of solid tumours: a review of clinical trialsPharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studyHistone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Targeting Histone Deacetylases in Diseases: Where Are We?Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplan
P2860

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.

Item
http://www.wikidata.org/entity/Q33408584
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacokinetic/pharmacodynami ...... (S78454/PCI-24781) in phase I.
@ast
Pharmacokinetic/pharmacodynami ...... (S78454/PCI-24781) in phase I.
@en
type
label
Pharmacokinetic/pharmacodynami ...... (S78454/PCI-24781) in phase I.
@ast
Pharmacokinetic/pharmacodynami ...... (S78454/PCI-24781) in phase I.
@en
prefLabel
Pharmacokinetic/pharmacodynami ...... (S78454/PCI-24781) in phase I.
@ast
Pharmacokinetic/pharmacodynami ...... (S78454/PCI-24781) in phase I.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Pharmacokinetic/pharmacodynami ...... (S78454/PCI-24781) in phase I.
@en
P2093
P304
P31
P356
10.1016/J.EJCA.2013.05.009
P433
P478
P50
P577
P698